Deutsch 
The study by Sommariva E et al. (2021) demonstrates that oxLDL can be used as a predictive marker for the progression of arrhythmogenic cardiomyopathy (ACM). Based on the cut-off of 86 ng/mL, patients with ACM were divided into 2 groups and further studied.
Levels < 86 ng/mL included among other things a lower risk of cardiovascular events (such as ventricular tachycardia, ventricular fibrillation, sudden cardiac death), improved cardiac function, and low fatty infiltration in the heart.
Thus, the oxLDL/MDA Adduct ELISA of IDK® can not only detect particularly small, modified oxLDL particles (Pfützner A et al.; 2009) and thus indicate changes in atherosclerosis risk, but can also be used as a predictive marker for arrhythmogenic cardiomyopathies.
Further source:
Pfützner A, Efstrathios K, Löbig M, Armbruster FP, Hanefeld M, Forst T. Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study. Clin Lab. 2009;55(7-8):275-81. PMID: 19894406.
